EP2800577A2 - Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70) - Google Patents
Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70)Info
- Publication number
- EP2800577A2 EP2800577A2 EP13733755.6A EP13733755A EP2800577A2 EP 2800577 A2 EP2800577 A2 EP 2800577A2 EP 13733755 A EP13733755 A EP 13733755A EP 2800577 A2 EP2800577 A2 EP 2800577A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- hsp70
- tumors
- carcinoma
- administered
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261583535P | 2012-01-05 | 2012-01-05 | |
PCT/US2013/020252 WO2013103792A2 (en) | 2012-01-05 | 2013-01-04 | Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70) |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2800577A2 true EP2800577A2 (en) | 2014-11-12 |
Family
ID=48745538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13733755.6A Withdrawn EP2800577A2 (en) | 2012-01-05 | 2013-01-04 | Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70) |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2800577A2 (en) |
JP (1) | JP2015515445A (en) |
AU (1) | AU2013207466A1 (en) |
CA (1) | CA2858427A1 (en) |
IL (1) | IL232732A0 (en) |
WO (1) | WO2013103792A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202019398A (en) * | 2018-06-28 | 2020-06-01 | 張翔毓 | Methods for treating or preventing conformation diseases and methods for drug screening |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE297750T1 (en) * | 1998-03-27 | 2005-07-15 | Gabriele Prof Dr Multhoff | USE OF HSP70 PROTEIN |
PL2659904T3 (en) * | 2008-06-26 | 2016-01-29 | Orphazyme Aps | Use of Hsp70 as a regulator of enzymatic activity |
-
2013
- 2013-01-04 JP JP2014551330A patent/JP2015515445A/en active Pending
- 2013-01-04 AU AU2013207466A patent/AU2013207466A1/en not_active Abandoned
- 2013-01-04 CA CA2858427A patent/CA2858427A1/en not_active Abandoned
- 2013-01-04 WO PCT/US2013/020252 patent/WO2013103792A2/en active Application Filing
- 2013-01-04 EP EP13733755.6A patent/EP2800577A2/en not_active Withdrawn
-
2014
- 2014-05-21 IL IL232732A patent/IL232732A0/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2013103792A3 * |
Also Published As
Publication number | Publication date |
---|---|
IL232732A0 (en) | 2014-07-31 |
AU2013207466A1 (en) | 2014-06-12 |
WO2013103792A3 (en) | 2015-01-22 |
CA2858427A1 (en) | 2013-07-11 |
WO2013103792A2 (en) | 2013-07-11 |
JP2015515445A (en) | 2015-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maverakis et al. | Metastatic melanoma–a review of current and future treatment options | |
Nakamura et al. | Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma | |
Moertel et al. | CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy | |
KR101183705B1 (en) | Therapeutic agent for cancer | |
Cowawintaweewat et al. | Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment | |
US20220401474A1 (en) | Hdac6-activated macrophages, compositions, and uses thereof | |
Ashrafi et al. | Anti-tumor effects of propranolol: Adjuvant activity on a transplanted murine breast cancer model | |
Boone et al. | Targeting damage-associated molecular pattern molecules (DAMPs) and DAMP receptors in melanoma | |
US20130273002A1 (en) | Multivalent breast cancer vaccine | |
Wang et al. | Methionine enkephalin inhibits colorectal cancer by remodeling the immune status of the tumor microenvironment | |
US20210363224A1 (en) | IL13Ra2 PEPTIDE AND ITS USES | |
WO2013103792A2 (en) | Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70) | |
CN105025916B (en) | Use of Antisecretory Factor (AF) in the treatment of glioblastoma | |
US20140194368A1 (en) | Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70) | |
US11946094B2 (en) | Combination therapies and methods of use thereof | |
TW202128212A (en) | Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug | |
CN101224297A (en) | Application of recombinant human endostain in preparing medicine | |
CN113382744A (en) | Manipulation of meningeal lymphatic vessels for brain and CNS tumors | |
US20200000899A1 (en) | Pharmaceutical composition for use in the treatment of cancer | |
Zhang | Effect of immunotherapy combined with intravenous chemotherapy on the tumor load, immune function and cancer cell proliferation activity in patients with advanced colon cancer | |
KR20200038942A (en) | Pharmaceutical kit and its use | |
RU2794024C1 (en) | Set of drugs for conducting a course of tertiary prevention of oncological diseases for immunomodulatory effects in combination therapy and a method for tertiary prevention of oncological diseases using combination therapy using a set of drugs for immunomodulating effects | |
Qianqi et al. | Efficacy and safety of transarterial infusion of anti-PD-1 in the treatment of advanced or metastatic acral and mucosal melanomas | |
Gao et al. | Tumoral IL-10-activated SHP2 in macrophages promotes mammary carcinoma progression | |
Akan et al. | Role of HSP in the Treatment of Internal Diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140603 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
R17D | Deferred search report published (corrected) |
Effective date: 20150122 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 21/04 20060101ALI20150211BHEP Ipc: A61K 38/16 20060101ALI20150211BHEP Ipc: C07K 1/00 20060101ALI20150211BHEP Ipc: C12N 5/00 20060101AFI20150211BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160802 |